Leucine-phenylalanine dipeptide-based N-mesyloxysuccinimides: Synthesis of all four stereoisomers and their assay against serine proteases

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 3, 1999, Pages 497-500

  Abell, Andrew D ^a   Oldham, Mark D ^a  

^a UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 (N ACETYLLEUCYLAMINO) 3 BENZYL 1 [(METHYLSULFONYL)OXY]SUCCINIMIDE; CHYMOTRYPSIN A; LEUKOCYTE ELASTASE; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; STEREOISOMERISM;

CHYMOTRYPSIN; DIPEPTIDES; HUMANS; LEUCINE; LEUKOCYTE ELASTASE; PHENYLALANINE; SERINE PROTEINASE INHIBITORS; STEREOISOMERISM; SUCCINIMIDES;

OXY;

EID: 0033535070     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00017-7     Document Type: Article

References (22)

1. Abell, A. D. in Detailed Reaction Mechanisms: Mechanisms of Biological Importance; Coxon, J., Ed.; JAI: London, 1992; Vol. 2, pp 243-260.
2. Silverman, R. B. in Mechanism-based Enzyme Inactivation: Chemistry and Enzymology; CRC: Florida, 1988; Vol 1 and 2.
3. Babine, R. E.; Bender, S. L. Chem. Rev. 1997, 97, 1359.
4. (a) Groutas, W. C; Brubaker, M. J.; Chong, M. A. L. S.; Epp, J. B.; Huang, H.; Keller, C. E.; McClenahan, J. J.; Givens, R. S.; Singh, R.; Zandler, M. E.; Karr, P. A.; Tagusagawa, F. Drug Design and Discovery 1994, 11, 149.
5. (b) Groutas, W. C; Brubaker, M. J.; Stanga, M. A.; Castrisos, J. C.; Crowley, J. P.; Schatz, E. J. J. Med. Chem. 1989, 32, 1607.
6. (c) Groutas, W. C.; Stanga, M. A.; Brubaker, M. J. J. Am. Chem. Soc. 1989, 111, 193.
7. (a) Abell, A. D.; Oldham, M. D. J. Org. Chem. 1997, 62, 1509.
8. (b) Abell, A. D.; Edwards, R. A; Oldham, M. D. J. Chem. Soc., Perkin Trans. 1 1997, 1655.
9. Abell, A. D.; Taylor, J. M.; Oldham, M. D. J. Chem. Soc., Perkin Trans. 1 1996, 1299.
10. (a) Seebach, D.; Fadel, A. Helv. Chim. Acta 1985, 68, 1243.
11. (b) Williams, R. M. in Synthesis of Optically Active α-Amino Acids; Baldwin, J.; Magnus, P. D. Eds.; Pergamon: Oxford, 1989, Vol 7.
12. 5b,7
13. 1H NMR spectra of 8-13 were dependent on the concentration of the sample used in the analysis.
14. (a) Kitz, R.; Wilson, I. B. J. Biol. Chem. 1962, 237, 3245.
15. (b) Chakravarty, P. K.; Krafft, G. A.; Katzenellenbogen, J. A. J. Biol. Chem. 1982, 257, 610.
16. (c) Oleksyszyn, J.; Powers, J. C. Biochemistry 1991, 30, 485.
17. 14
18. It is also well documented that the greater the substitution on a cyclic compound (e.g. as in a succinimide) the less prone it is to ring-opening (see Allinger, N. L.; Zalkow, V. J. Org. Chem. 1960, 25, 701). On this basis, at least, it might be expected that compounds of the type 10 and 13 would be less susceptible than 1 to the ring-opening step required to give enzyme inactivation.
19. For a definition of this nomenclature see: Schechter, I.; Berger, A. Biochem. Biophys. Res. Commun. 1967, 27, 157.
20. Fersht, A. Enzyme Structure and Mechanism, 2nd Ed.; W. H. Freeman and Company: New York, 1985; pp 17-22.
21. (a) Ohba, T.; Ikeda, E.; Wakayama, J.; Takei, H. Bioorg. Med. Chem. Lett. 1996, 6, 219.
22. (b) Daniels, S. B.; Cooney, E.; Sofia, M. J.; Chakravarty, P. K.; Katzenellenbogen, J. A. J. Biol. Chem. 1983, 258, 15046.